

Patient ID SAMPLE	Patient Name PATIENT, TEST	Birth Date 1974-08-04	Sex M	Age 50
Order Number SAMPLE	Client Order Number SAMPLE	Ordering Physician SAMPLE	Report Notes Sample Report	
Account Information SAMPLE		Collected 05 Aug 2024 10:16		

CD8 Immune Competence, B

IFN-g

!

Low

2.7 % CD8 T-Cells

SDL

Reference Value
10.3–56.0

CD107a/b

!

Low

1.3 % CD8 T-Cells

SDL

Reference Value
8.5–49.1

Interpretation

Decreased IFN-gamma production and CD107a/b expression after CD8 T cell stimulation. This result, on prima facie evidence, would suggest relatively significant immunosuppression, at least within the CD8 T cell compartment, likely related to post-

transplant immunosuppression; though it is possible that there may be polyfunctional CD8 T cells present, producing other cytokines, such as TNF-alpha and/or IL-2 on activation instead of IFN-gamma. However, the decreased CD107 expression tends to support the former rather than the latter possibility. Correlate with other relevant immunological parameters and clinical status to assess the potential extent of immune compromise. Patient can be re-assessed for T cell function 1–2 weeks after reduction in Cellcept dose and also if steroids are decreased or weaned.

ADDITIONAL INFORMATION

CD107a and CD107b are markers of cellular degranulation and surrogate markers for cytotoxic function.

Received: 06 Aug 2024 10:11 Reported: 06 Aug 2024 10:16

Laboratory Notes

1 Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592